Biotechnology companies Cue Biopharma and ImmunoScape have entered into a collaboration and license agreement to advance cell therapies for the treatment of solid tumours.  Under the agreement, ImmunoScape will develop a novel ‘Seed-and-Boost’ immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers with ImmunoScape’s proprietary TCRs. The combination therapy is designed to overcome core limitations of existing cell therapies with the potential for establishing a breakthrough standard of care […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!